Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11930010 | 0.86 | SMN1; SMN2 (0.37) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL22648378 | 0.84 | KDM4E (0.36) | SMN1; SMN2POLB | |
| SCHEMBL9427327 | 0.81 | NPSR1 (0.32) | NPSR1MEN1KMT2AFAAHNAAA | |
| SCHEMBL6064712 | 0.81 | NPSR1 (0.35) | NPSR1MEN1KMT2AFAAHNAAA | |
| SCHEMBL13672148 | 0.79 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL26452801 | 0.78 | NPSR1 (0.37) | NPSR1FAAHNAAAPOLBALDH1A1 | |
| SCHEMBL25687381 | 0.78 | MEN1 (0.35) | NPSR1MEN1KMT2AFAAHNAAA | |
| SCHEMBL19187971 | 0.76 | PIK3CD (0.31) | — | |
| SCHEMBL12643440 | 0.76 | MEN1 (0.31) | MEN1KMT2AFAAHNAAASMN1; SMN2 | |
| SCHEMBL28956101 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010025871-A1 | 4-HALOGEN ALKYL-SUBSTITUTED DIAMINOPYRIMIDINES FOR USE AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2010-03-11 | — | — | WO | claimed |
| WO-2025094987-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING SULFONYL GROUP, AGRICULTURAL/HORTICULTURAL HERBICIDE CONTAINING SAME, AND USE THEREOF | 日本農薬株式会社 | 2025-05-08 | — | — | WO | disclosed |
| US-20240226107-A1 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240226107-A1 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240217974-A1 | ISOQUINOLONE COMPOUND AND USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240217974-A1 | ISOQUINOLONE COMPOUND AND USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-11851425-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines | H. LUNDBECK A/S (DK) | 2023-12-26 | — | — | US | disclosed |
| US-11795315-B2 | Group 5 metal complexes for producing amine-functionalized polyolefins | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-10-24 | — | — | US | disclosed |
| US-11795315-B2 | Group 5 metal complexes for producing amine-functionalized polyolefins | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-10-24 | — | — | US | disclosed |
| US-11795315-B2 | Group 5 metal complexes for producing amine-functionalized polyolefins | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2023-10-24 | — | — | US | disclosed |
| US-7420066-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| WO-2008083027-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | WO | disclosed |
| US-20080161280-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
| US-20070293508-A1 | Crf Receptor Antagonists and Methods Relating Thereto | SB PHARMCO PUERTO RICO INC AND NEUROCRINE BIOSCIENCES, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070265446-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | CONNOLLY TERRENCE J | 2007-11-15 | — | — | US | disclosed |
| US-20070265446-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | CONNOLLY TERRENCE J | 2007-11-15 | — | — | US | disclosed |
| US-7244738-B2 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC (US) | 2007-07-17 | — | — | US | disclosed |
| US-7244738-B2 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ROCHE PALO ALTO LLC (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265446-A1 | Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists | ADRB1, ADRA1A, ADRA1B | NPSR1 85/4885MEN1 3414/4885KMT2A 2952/4885 |
| US-20070293508-A1 | Crf Receptor Antagonists and Methods Relating Thereto | CRHR1, CRHR2, SCTR | NPSR1 13/4885MEN1 1530/4885KMT2A 3695/4885 |
| US-11851425-B2 | Combination treatments comprising administration of 1H-pyrazolo[4,3-B]pyridines | PDE3B, PDE1B, PDE12 | NPSR1 408/4885MEN1 2306/4885KMT2A 2116/4885 |
| US-20240226107-A1 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | USP1, USP2, USP3 | NPSR1 2655/4885MEN1 2323/4885KMT2A 1401/4885 |
| US-20240217974-A1 | ISOQUINOLONE COMPOUND AND USE THEREOF | CYP4A11, CYP11B2, NQO1 | NPSR1 1564/4885MEN1 1689/4885KMT2A 1050/4885 |
| US-20080161280-A1 | INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE | PARP1, PARP2, PARP3 | NPSR1 3160/4885MEN1 3538/4885KMT2A 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.